Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 1/20 | 0.51 |
| ▸ | CA12 | O43570 | 1/20 | 0.48 |
| ▸ | CA1 | P00915 | 1/20 | 0.48 |
| ▸ | CA2 | P00918 | 1/20 | 0.48 |
| ▸ | CA4 | P22748 | 1/20 | 0.48 |
| ▸ | CA7 | P43166 | 1/20 | 0.48 |
| ▸ | CA9 | Q16790 | 1/20 | 0.48 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.46 |
| ▸ | ACR | P10323 | 1/20 | 0.46 |
| ▸ | CARM1 | Q86X55 | 1/20 | 0.46 |
| ▸ | PRMT6 | Q96LA8 | 1/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.45 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7976424 | 1.00 | KMT2A (0.51) | KMT2ACA12CA1CA2CA4 | |
| Hydrochloric Acid SCHEMBL11263322 | 0.98 | KMT2A (0.50) | KMT2ACA12CA1CA2CA4 | |
| SCHEMBL4090809 | 0.85 | KMT2A (0.55) | KMT2ACA12CA1CA2CA4 | |
| SCHEMBL31053800 | 0.85 | KMT2A (0.55) | KMT2ACA12CA1CA2CA4 | |
| SCHEMBL3361719 | 0.83 | KMT2A (0.53) | KMT2ACA12CA1CA2CA4 | |
| SCHEMBL27999260 | 0.82 | IRAK4 (0.62) | KMT2AKDM4ELMNAALDH1A1MAPT | |
| SCHEMBL24023413 | 0.81 | KMT2A (0.51) | KMT2ACA12CA1CA2CA4 | |
| SCHEMBL5062924 | 0.81 | TDP1 (0.46) | KMT2AKDM4EALDH1A1L3MBTL1ATM | |
| SCHEMBL5058437 | 0.81 | TDP1 (0.46) | KMT2AKDM4EALDH1A1L3MBTL1ATM | |
| SCHEMBL8399530 | 0.81 | CA1 (0.45) | KMT2ACA12CA1CA2CA7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0950046-B1 | 3,4-DISUBSTITUTED AZETIDIN-2-ONE DERIVATIVES USEFUL AS CYSTEINE PROTEINASE REGULATORS | NAEJA PHARMACEUTICAL INC (CA) | 2002-04-10 | — | — | EP | claimed |
| CN-104387372-B | Oxo azetidine derivatives, preparation method and its purposes in human medical and cosmetics | 盖尔德马研究及发展公司 | 2018-06-26 | — | — | CN | disclosed |
| EP-1679302-B1 | AROMATIC AMINO ACID LABELED WITH STABLE ISOTOPE, METHOD FOR INCORPORATING THE SAME INTO TARGET PROTEIN AND METHOD FOR ANALYZING PROTEIN STRUCTURE USING NMR | JAPAN SCIENCE & TECH AGENCY (JP) | 2014-04-30 | — | — | EP | disclosed |
| US-8440169-B2 | Stable isotope-labeled aromatic amino acids, method for incorporating the same in target protein and method for NMR-structural analysis of proteins | JAPAN SCIENCE AND TECHNOLOGY AGENCY (JP) | 2013-05-14 | — | — | US | disclosed |
| US-20100056799-A1 | Stable Isotope-Labeled Aromatic Amino Acids, Method for Incorporating the Same in Target Protein and Method for NMR-Structural Analysis of Proteins | JAPAN SCIENCE AND TECHNOLOGY AGENCY (JP) | 2010-03-04 | — | — | US | disclosed |
| US-7608248-B2 | Stable isotope-labeled aromatic amino acids, method for incorporating the same in target protein and method for NMR-structural analysis of proteins | JAPAN SCIENCE AND TECHNOLOGY AGENCY (JP) | 2009-10-27 | — | — | US | disclosed |
| US-20060194328-A1 | Stable isotope-labeled aromatic amino acids, method for incorporating the same in target protein and method for NMR-structural analysis of proteins | JAPAN SCIENCE AND TECHNOLOGY AGENCY | 2006-08-31 | — | — | US | disclosed |
| EP-1679302-A1 | AROMATIC AMINO ACID LABELED WITH STABLE ISOTOPE, METHOD FOR INCORPORATING THE SAME INTO TARGET PROTEIN AND METHOD FOR ANALYZING PROTEIN STRUCTURE USING NMR | Japan Science and Technology Agency (JP) | 2006-07-12 | — | — | EP | disclosed |
| WO-2006009623-A1 | DETECTION OF PROTEIN EXPRESSION IN VIVO USING FLUORESCENT PUROMYCIN CONJUGATES | CALIFORNIA INSTITUTE OF TECHNOLOGY (US) | 2006-01-26 | — | — | WO | disclosed |
| EP-0013261-B1 | GUAIACOL ESTERS OF ALPHA- AND BETA-MERCAPTOPROPIONYLALANINE AND ALPHA- AND BETA-MERCAPTOPROPIONYLGLYCINE, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAME | Sigma-Tau Industrie Farmaceutiche Riunite S.p.A. (IT) | 1982-12-01 | — | — | EP | disclosed |
| US-4299842-A | TREATMENT OF RESPIRATORY SYSTEM DISORDERS, NUCOLYTIC AGENTS | CAVAZZA CLAUDIO | 1981-11-10 | — | — | US | disclosed |
| EP-0013261-A1 | Guaiacol esters of alpha- and beta-mercaptopropionylalanine and alpha- and beta-mercaptopropionylglycine, process for their preparation and pharmaceutical compositions containing same | Sigma-Tau Industrie Farmaceutiche Riunite S.p.A. (IT) | 1980-07-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100056799-A1 | Stable Isotope-Labeled Aromatic Amino Acids, Method for Incorporating the Same in Target Protein and Method for NMR-Structural Analysis of Proteins | BCAT1, DDC, PAH | KMT2A 2489/4885CA12 619/4885CA1 965/4885 |
| US-20060194328-A1 | Stable isotope-labeled aromatic amino acids, method for incorporating the same in target protein and method for NMR-structural analysis of proteins | BCAT1, DDC, PAH | KMT2A 2489/4885CA12 619/4885CA1 965/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.